Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XC25
|
| gptkbp:brand |
Besponsa
|
| gptkbp:CASNumber |
746832-22-2
|
| gptkbp:contains |
humanized anti-CD22 monoclonal antibody
ozogamicin |
| gptkbp:developer |
gptkb:Pfizer
|
| https://www.w3.org/2000/01/rdf-schema#label |
inotuzumab ozogamicin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
binds to CD22 and delivers cytotoxic agent
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
hepatotoxicity
infusion reactions myelosuppression veno-occlusive disease |
| gptkbp:target |
gptkb:CD22
|
| gptkbp:UNII |
8Q2K6F6F2K
|
| gptkbp:usedFor |
leukemia
|
| gptkbp:bfsParent |
gptkb:CD22
|
| gptkbp:bfsLayer |
7
|